20/20 BioLabs Partners with ROKIT Healthcare to Integrate CKD Prediction Technology into Longevity Testing Platform
核心洞察
20/20 BioLabs (搜索) has secured an exclusive U.S. license agreement with ROKIT Healthcare (搜索) to integrate advanced chronic kidney disease prediction algorithms into its OneTest for Longevity (搜索) platform.
The partnership combines inflammatory biomarker tracking with CKD risk assessment, targeting the more than 35 million Americans affected by chronic kidney disease.
Clinical evidence suggests patients with lower systemic inflammation show more favorable responses to ROKIT's 3-D bio-printed tissue patches for burns, chronic kidney disease, and heart failure.
20/20 BioLabs (搜索), Inc. (Nasdaq: AIDX) announced on March 24, 2026, that it has entered into an exclusive U.S. technology license and access agreement with ROKIT Healthcare (搜索) Inc., a global innovator in chronic disease prediction and regenerative health technologies. The partnership will integrate ROKIT's proprietary chronic kidney disease (CKD) prediction algorithm into 20/20's Longevity Platform, expanding its suite of biomarker-based disease-risk assessment tools.
Strategic Partnership Structure
Under the agreement, ROKIT will reimburse 20/20 for one-third of mutually agreed sales and marketing expenses in exchange for a running royalty on net sales of the combined product. The companies are also exploring a separate agreement that would grant ROKIT exclusive rights to commercialize 20/20's longevity platform in Korea and potentially other East Asian markets.
Clinical Rationale and Therapeutic Synergy
The partnership is grounded in clinical evidence suggesting that patients with lower systemic inflammation, as measured by biomarkers such as C-reactive protein (CRP), tend to experience more favorable biological responses to regenerative therapies. CRP serves as the centerpiece of OneTest for Longevity (搜索), which launched in February 2026.
"20/20 Biolabs (搜索) has created an elegant solution to help patients lower their levels inflammatory biomarkers through evidence based dietary and lifestyle changes," noted Wonkyung Choi, Vice President of R&D at ROKIT Healthcare (搜索). "We expect that patients being treated for burns or chronic kidney disease using our 3-D bio-printed patches will likely have better outcomes if they can lower their inflammation and maintain those low levels through biomarker tracking and better food choices over time using OneTest for Longevity (搜索)."
Market Impact and Disease Burden
The addition of CKD prediction capabilities enhances 20/20's competitive position in the rapidly expanding longevity-analytics sector. Chronic kidney disease affects more than 35 million Americans, and early detection remains one of the most effective strategies for slowing disease progression. By integrating ROKIT's predictive model, 20/20 aims to deliver earlier insights, more personalized risk trajectories, and improved decision-support tools for individuals and their healthcare providers.
Technology Integration
20/20 BioLabs (搜索) develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. The company offers two families of lab tests under the OneTest brand: OneTest for Cancer (搜索), a multi-cancer early detection blood test, and OneTest for Longevity (搜索), which measures inflammatory biomarkers.
The tests utilize upper arm collection devices that avoid painful needles and are processed in the company's College of American Pathologists (CAP) accredited, Clinical Laboratory Improvement Amendments (CLIA) licensed laboratory in Gaithersburg, Maryland.
Executive Perspective
"This agreement is a strong validation of our platform strategy," said Jonathan Cohen, President & CEO of 20/20 Biolabs (搜索). "We believe that combining advanced biomarker tracking with evidence based nutritional support will help improve therapeutic outcomes across multiple chronic disease areas."
ROKIT Healthcare (搜索), listed on KOSDAQ, specializes in regenerative medicine, predictive health analytics, and 3-D bioprinting technologies. The company develops advanced algorithms and regenerative solutions aimed at improving outcomes in chronic disease and tissue repair, including 3-D bio-printed tissue patches for burns, chronic kidney disease, and heart failure.